<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03480984</url>
  </required_header>
  <id_info>
    <org_study_id>17-009991</org_study_id>
    <nct_id>NCT03480984</nct_id>
  </id_info>
  <brief_title>Continuous Versus Intermittent Bolus Infusion of Paravertebral Blocks for Thoracic Surgery</brief_title>
  <official_title>A Comparison Between Continuous Versus Intermittent Bolus Infusion of Paravertebral Blocks for Thoracic Surgery: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The researchers are trying to determine pain medication consumption in the first 24 hours
      after surgery in patients given the standard continuous infusion of local anesthetic versus
      patients given the same total dose via programmed intermittent dosing. Both groups will
      receive the option of patient controlled pain medication as well as the same dose of
      pre-programmed pain medication. The only difference is the rate of administration: continuous
      vs. hourly intervals.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 5, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Investigators will not have direct access to settings on the pump</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid consumption 24 hours postoperatively</measure>
    <time_frame>first 24 hours postoperatively</time_frame>
    <description>morphine equivalents of opioids in mg will be obtained from medical record</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid consumption 48 hours postoperatively</measure>
    <time_frame>first 48 hours postoperatively</time_frame>
    <description>morphine equivalents of opioids in mg will be obtained from medical record</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Thoracic Diseases</condition>
  <arm_group>
    <arm_group_label>Programmed Intermittent Bolus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via an hourly programmed bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous Infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via continuous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Programmed Intermittent Bolus</intervention_name>
    <description>6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via an hourly programmed bolus</description>
    <arm_group_label>Programmed Intermittent Bolus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Continuous Infusion</intervention_name>
    <description>6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via continuous infusion</description>
    <arm_group_label>Continuous Infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documentation of planned thoracic surgery for which a paravertebral catheter is
             indicated based on surgeon request as well as appropriateness of location of surgical
             site.

          -  Ability for subject to comply with the requirements of the study.

        Exclusion Criteria:

          -  Pregnancy.

          -  Coagulopathy at time of evaluation or surgery.

          -  Infection at the site of needle insertion.

          -  Allergy to local anesthetic.

          -  Patient refusal.

          -  Chronic opioid use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elird Bojaxhi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Elird Bojaxhi, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thoracic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

